(S (NP (NN Phase) (PRP I) (JJ dose-finding) (NNS trials)) (VP (VBP are) (ADJP (RB increasingly) (VBG challenging)) (SBAR (IN as) (S (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NN efficacy) (CC and) (NN toxicity)) (PP (IN of) (NP (NP (JJ new) (NNS compounds)) (PRN (-LRB- -LRB-) (CC or) (NP (NP (NN combination)) (PP (IN of) (NP (PRP them)))) (-RRB- -RRB-))))))) (VP (VBZ becomes) (ADJP (RBR more) (JJ complex)))))) (. .))
(S (PP (IN Despite) (NP (DT this))) (, ,) (NP (NP (ADJP (ADVP (JJS most) (RB commonly)) (VBN used)) (NNS methods)) (PP (IN in) (NP (NN practice)))) (VP (NN focus) (PP (IN on) (S (VP (VBG identifying) (NP (NP (DT a) (NNP Maximum) (NNP Tolerated) (NNP Dose)) (PRN (-LRB- -LRB-) (NP (NNP MTD)) (-RRB- -RRB-))) (PP (IN by) (S (VP (VBG learning) (PP (ADVP (RB only)) (IN from) (NP (NN toxicity) (NNS events)))))))))) (. .))
(S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (JJ novel) (JJ adaptive) (JJ clinical) (NN trial) (NN methodology)) (, ,) (VP (VBN called) (S (NP (S (NP (NNP Safe) (NNP Efficacy) (NNP Exploration) (NNP Dose) (NNP Allocation))) (PRN (-LRB- -LRB-) (NP (NNP SEEDA)) (-RRB- -RRB-))))) (, ,) (SBAR (WHNP (IN that)) (S (VP (VBZ aims) (PP (IN at) (S (VP (VBG maximizing) (NP (DT the) (JJ cumulative) (NNS efficacies)) (SBAR (IN while) (S (VP (VBG satisfying) (NP (DT the) (NN toxicity) (NN safety) (NN constraint)) (PP (IN with) (NP (JJ high) (NN probability)))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP evaluate) (NP (NP (NN performance) (NNS objectives)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (NP (JJ operational) (NNS meanings)) (PP (IN in) (NP (JJ practical) (JJ clinical) (NNS trials)))))) (, ,) (PP (VBG including) (NP (NP (JJ cumulative) (NN efficacy)) (, ,) (NP (NN recommendation/allocation) (NN success) (NNS probabilities)) (, ,) (NP (NN toxicity) (NN violation) (NN probability)) (, ,) (CC and) (NP (JJ sample) (NN efficiency)))))) (. .))
(S (NP (NP (DT An) (JJ extended) (NNP SEEDA-Plateau) (NN algorithm)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN tailored) (PP (IN for) (NP (NP (DT the) (JJ increase-then-plateau) (NN efficacy) (NN behavior)) (PP (IN of) (NP (NP (ADJP (RB molecularly) (VBN targeted)) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NNP MTA)) (-RRB- -RRB-))))))))))) (VP (VBZ is) (ADVP (RB also)) (VP (VBN presented))) (. .))
(S (PP (IN Through) (NP (NP (JJ numerical) (NNS experiments)) (VP (VBG using) (NP (UCP (DT both) (JJ synthetic) (CC and) (JJ real-world)) (NNS datasets))))) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP SEEDA)) (VP (VBZ outperforms) (NP (JJ state-of-the-art) (JJ clinical) (NN trial) (NNS designs)) (PP (IN by) (S (VP (VBG finding) (NP (DT the) (JJ optimal) (NN dose)) (PP (IN with) (NP (NP (JJR higher) (NN success) (NN rate)) (CC and) (NP (JJR fewer) (NNS patients))))))))))) (. .))
